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Abstract
Background: SB623 cells are expanded from marrow stromal cells (MSCs) transfected with a Notch intracellular
domain (NICD)-expressing plasmid. In stroke-induced animals, these cells reduce infarct size and promote
functional recovery. SB623 cells resemble the parental MSCs with respect to morphology and cell surface markers
despite having been in extended culture. MSCs are known to have immunosuppressive properties; whether long-
term culture of MSCs impact their immunomodulatory activity has not been addressed.
Methods: To assess the possible senescent properties of SB623 cells, we performed cell cycle related assays and
beta-galactosidase staining. To assess the immunomodulatory activity of these expanded NICD-transfected MSCs,
we performed co-cultures of SB623 cells or MSCs with either enriched human T cells or monocytes and assessed
cytokine production by flow cytometry. In addition, we monitored the immunosuppressive activity of SB623 cells in
both allogenic and xenogenic mixed lymphocyte reaction (MLR).
Results: Compared to MSCs, we showed that a small number of senescent-like cells appear in each lot of SB623
cells. Nevertheless, we demonstrated that these cells suppress human T cell proliferation in both the allogeneic
and xenogeneic mixed lymphocyte reaction (MLR) in a manner comparable to MSCs. IL-10 producing T cells were
generated and monocyte-dendritic cell differentiation was dampened by co-culture with SB623 cells. Compared to
the parental MSCs, SB623 cells appear to exert a greater inhibitory impact on the maturation of dendritic cells as
demonstrated by a greater reduction in the surface expression of the co-stimulatory molecule, CD86.
Conclusion: The results demonstrated that the immunosuppressive activity of the expanded NICD-transfected
MSCs is comparable to the parental MSCs, in spite of the appearance of a small number of senescent-like cells.
Introduction
There is an important need for stromal cell lines that
support neural cells and the mesenchymal stem cell
(MSC) line SB623, transfected with the Notch-intracel-
lular domain (NICD), appear to meet these criteria. In
cultures of embryonic cortical neurons, SB623 cells pro-
duce extracellular matrix proteins which enhance and
maintain neurite outgrowth [1]. In neonatal hippocam-
pal organotypic culture, SB623 cell-derived soluble
trophic factors rescue neural cells subjected to oxygen-
glucose deprivation [2]. In experimental Parkinson’s dis-
ease, grafting of SB623 cells efficiently reverses the
degeneration of dopaminergic neurons by promoting
endogeneous neuronal cell recovery [3,4]. And in stable
stroke animal models, transplantation of SB623 cells
reduces infarct size and promotes behavioral improve-
ment [5]. These studies validate one of the therapeutic
applications of SB623 cells - to supply trophic factors
for the endogenous neural cells after injury or disease.
Human marrow stromal cells are attractive for cell
therapy because they can be obtained with minimal
invasiveness and can be expanded in culture. However,
as non-immortalized primary cells, MSCs have limited
regenerative potential, committing to cellular senescence
after extensive ex vivo manipulation [6,7]. A potential
upside of senescent cells is their robust cytokine secre-
tome profile which could be beneficial in tissue regen-
eration. A potential downside is that the senescent-
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matory [8-10]. To date, intracerebral implantation of
human SB623 cells in stroke-induced animals has not
triggered any immunological adverse effect. Neverthe-
less, as SB623 cells are derived from MSCs that have
undergone gene transfection and cell expansion in cul-
t u r e ,w ei n i t i a t e dt h ec u r r e n ts t u d yt od e t e r m i n e
whether SB623 cells display senescent-like properties.
More importantly, we compare the immunomodulatory
activity between SB623 cells and the corresponding par-
ental MSCs. We demonstrate that SB623 cells, currently
in a clinical trial for stable stroke (http://clinicaltrials.
gov/ct2/show/NCT01287936), retain the immunosup-
pressive activity of standard MSCs despite the appear-
ance of a small number of senescent-like cells.
Materials and methods
Production of MSCs and SB623 cells
MSC and SB623 cells were produced as previously
reported [1,2]. Briefly, human adult bone marrow aspi-
rates (Lonza, Walkersville, MD) were plated in growth
medium - aMEM (Mediatech, Manassas, VA) supple-
mented with 10% fetal bovine serum (FBS) (Hyclone,
Logan, UT), 2 mM L-glutamine and penicillin/strepto-
mycin (both from Invitrogen, Carlsbad, CA) for three
days to obtain the marrow stromal cell (MSC) mono-
layer. After two passages, a portion of the culture was
cryopreserved as MSCs. The remaining cells (passage 2)
were transfected with the pCMV-hNICD1-SV40- Neo
R
plasmid using Fugene6 (Roche Diagnostics, Indianapolis,
IN). After 7 days of selection with 100 μg/ml G418
(Invitrogen), the G418-resistant colonies were expanded
and passed twice prior to cryopreservation as SB623
cells. This results in a uniformly transiently transfected
population of MSCs.
qPCR and qRT-PCR
Two days after transfection with pN2-NICD plasmid,
cells were lysed and DNA or RNA purified using Qia-
gen’s QIAAmp DNA or RNeasy mini kits (Qiagen,
Valencia, CA), correspondingly, according to the manu-
facturer’s protocols. Quantitative real time PCR or RT-
PCR analyses were conducted using QuantiTect Probe
PCR or RT-PCR kits, respectively, on Lightcycler
(Roche).
For exogenous-NICD (eNICD) qPCR analysis, purified
RNA-free DNA samples were used at 65 ng (10000
diploid human genomes) per reaction and eNICD gene
copy numbers were determined using eNICD-DNA-spe-
cific Taqman assay (forward primer: TTGGTCTTACT-
GACATCCACTTTG, reverse primer CAGACACTT
TGAAGCCCTCAG, exo-NICD-specific probe [6-FAM]
CCCAGTTCAATTACAGCTCTTAAGGCTAGAG
[BHQ1a-6FAM])). Amplification signals were compared
to those of pN2-NICD plasmid serially diluted in
human genomic DNA (Clontech, Mountain View, CA);
results expressed in numbers of plasmids per one
human diploid genome (plasmids/cell). For expression
analysis of a NICD target gene, human Hes1 and
GAPDH (control) Taqman assays (Applied Biosystems,
Carlsbad, CA) were used. Normalized Hes1 expression
levels are presented relative to levels in non-transfected
cells.
Phenotypic characterization by flow cytometry
For cell surface phenotyping, MSCs or SB623 cells were
harvested with 0.25% Trypsin/EDTA (Invitrogen),
washed in PBS/2% FBS, and re-suspended in 1 ml of
PBS/2% FBS. Cells were then stained with fluoro-
chrome-conjugated antibodies against CD29, CD31,
CD34, CD44, CD45, CD73, CD90 (all from BD Bios-
ciences, San Jose, CA) and CD105 (Invitrogen, Carlsbad,
CA) for 15 minutes on ice. After one wash in PBS/2%
FBS, cells were acquired using BD FACS Calibur. Ana-
lyses were done to assess the percentage of surface mar-
kers that are positive (CD29, CD44, CD73, CD90, and
CD105) versus negative (CD31, CD34, and CD45) for
mesenchymal cells using CellQuestPro program (BD
Biosciences). To compare the density of specific surface
molecule expression on MSCs versus SB623 cells, the
delta mean fluorescent intensity (dMFI) was calculated -
e.g., dMFI of CD44 = (MFI of CD44) - (MFI of IgG).
For intracellular protein detection of p16Ink4A and
NICD, cells were fixed with 4% paraformaldehyde and
permeabilized with PBS/0.1% TritonX-100. After two
washes in PBS/2% FBS, cell pellets were resuspended in
200 ul of PBS/2% FBS and divided into two tubes, one
for staining with phycoerythrin (PE)-conjugated IgG
(control) and the other for staining with PE-conjugated
p16Ink4A antibody (BD Bioscience) or PE-conjugated
NICD antibody (eBioscience). For intracellular cytokine
detection, cells were treated with BrefeldinA for six
hours prior to harvest. After fixation and permeabiliza-
tion, cells were incubated with fluorochrome-conjugated
antibody against human GM-CSF (BD Bioscience), IL-1a
(eBioscience, San Diego, CA), IL-6 (BD Bioscience),
TGFb1 (RnD Systems, Minneapolis, MN) for one hour
followed by two washes in PBS/2% FBS. Acquisition and
analysis of all samples were performed on BD FACS
Calibur using CellQuestPro software.
Cell proliferation measurement
To quantify viable cell expansion, one million MSCs or
SB623 cells were plated on Day 0 and cell counts by try-
pan blue exclusion were done on Day 3. For cell cycle
profile after culture, one million MSCs or SB623 cells
were fixed in 70% ethanol overnight at 4°C. After two
washes in PBS/2% FBS, cells were incubated in one ml
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RNAse) (Sigma, St. Louis, MO) in PBS/2% FBS for 30
m i ni nt h ed a r k .A c q u i s i t i o na n da n a l y s i sw e r ed o n e
using CellQuestPro program on the FL-2 linear channel.
For cell cycle kinetics over 5 days in culture, MSCs and
SB623 cells were labeled with 5 μM of 5-(and-6)-carbox-
yfluorescein diacetate (CFSE) (Invitrogen) for 2 min at
room temperature prior to culture. Flow cytometry
acquisition and analysis were done on the FL-1 log
channel.
Generation of monocyte-derived dendritic cells (Mono-
DC)
Peripheral blood was obtained from healthy donors and
mononuclear cells recovered from buffy coat prepara-
tions by Ficoll Paque (Amersham Pharmacia, Sweden)
gradient separation. Mononuclear cells were re-sus-
pended in RPMI/10%FBS and plated in a T-75 flask
overnight. Non-adherent cells were discarded and the
flasks were rinsed twice with PBS. Adherent monocytes
were recovered using 0.25% trypsin/2 mM EDTA. Purity
was assessed by staining with FITC-conjugated antibody
against human CD14, a monocyte surface marker (Bec-
ton Dickinson) and was routinely shown to be > 90%.
For monocytic-to-dendritic cell differentiation assays,
monocytes were cultured in RPMI-1640 (Mediatech)
containing 10% FBS, 2 mM glutamine, 2 mM sodium
pyruvate, 100 U/mL penicillin, 100 μg/mL streptomycin,
40 ng/mL granulocyte-macrophage colony stimulating
factor (GM-CSF) and 20 ng/mL interleukin-4 (IL-4)
(both from Peprotech, Rocky Hill, NJ) in the presence of
MSCs or SB623 cells at a 10:1 monocyte to MSC or
SB623 cell ratio. On Day 5, a subset of cultures were
harvested by 0.25% trypsin/2 mM EDTA and stained
with fluorochrome-conjugated antibodies against CD1a
and CD14 (eBioscience). Data acquisition and analysis
were done on the FACS Calibur using CellQuestPro
software.
To assess the impact of MSCs and SB623 cells on the
maturation of dendritic cells, monocyte-derived dendri-
tic cells were generated in the presence of GM-CSF and
I L - 4 .O nD a y5 ,h u m a nT N F - a (10 ng/ml; Peprotech)
was added to each well with or without MSCs or SB623
cells. As previous studies confirmed a role of cyclos-
porin A in hindering dendritic cell maturation [11],
addition of cyclosporin A (1 μg/ml; Santa Cruz Biotech-
nology, Santa Cruz, CA) in the absence of either MSCs
or SB623 cells was included as an internal control. On
Day 7, cells were incubated with a fluorochrome-conju-
gated monoclonal antibody against human CD86 (BD
Bioscience), a co-stimulatory molecule for priming and
activating naïve and memory T cells and analyzed on
the BD FACS Calibur using CellQuestPro.
Ex vivo culture of human peripheral blood T cells
Human T cells were enriched from peripheral blood
using the T-cell isolation kit (StemCell Technologies,
Vancouver, Canada) according to the manufacturer’s
protocol. Enriched T cells were cultured in RPMI-1640/
10% heat-inactivated FBS/pen/strep overnight prior to
use. On Day -1, 10,000 MSCs or SB623 cells were plated
per well of 96-well U-bottom plates. On Day 0 of the
culture assay, 100,000 enriched T cells were transferred
to each well with a pre-established MSC or SB623 cell
monolayer. As an internal control, T cell cultures were
maintained in the absence of MSCs or SB623 cells. On
Day 7, a sub-optimal dose of 25 ng/ml of phorbol 12-
myristate 13-acetate (PMA)/0.5 μM Ionomycin (both
from Sigma-Aldrich) was added in the presence of Bre-
feldinA (eBioscience, 1:1000) for 6 hours prior to har-
vest for intracellular detectiono fi n t e r l e u k i n - 1 0( I L - 1 0 )
and interferon gamma (IFN-g). For IL-17 producing
TH17 cells, T cells were co-cultured with SB623 cells or
MSCs in the presence of IL-23, or in the presence of IL-
23 alone. After sub-optimal activation with PMA/Iono-
mycin in the presence of BrefeldinA, the cells were
stained with fluorochrome-conjugated antibody against
IL-17A (eBioscience) and analyzed by flow cytometry.
For regulatory T cell culture, human enriched T cells
were co-cultured with MSCs or SB623 cells in the pre-
sence of human interleukin-2 (IL-2) (Peprotech, Rocky
Hill, NJ) at a 10:1 T cells to MSC or SB623 cell ratio for
7 days followed by cell surface staining for CD4, a
helper T cell marker and CD25, the IL-2 receptor alpha
chain. For FoxP3 intracellular staining, cells were fixed
and permeabilized with CytoFix/Perm (eBioscience). PE-
conjugated antibody against FoxP3 (clone PCH101,
eBioscience) was used at 1:50 dilution and flow cytome-
try analysis was done gating on lymphocytes. For assess-
ment of constitutive IL-10 production, intracellular
staining with fluorochrome conjugated antibody against
IL-10 was performed without PMA/Io stimulation on
Day 7.
Mixed lymphocyte reaction (MLR)
Human allogeneic mixed lymphocyte reaction was
established using peripheral blood from unrelated
healthy volunteers. To obtain responder cells, T cell
enrichment using a commercial T-cell rosette separation
kit (Stem Cell Technologies) was done based on the
manufacturer’s protocol. Enriched T cells (= responders)
were labeled with 5 μM of 5-(and-6)-carboxyfluorescein
diacetate (CFSE) (Invitrogen) for 2 min at room tem-
perature. CFSE-labeled lymphocytes were then plated in
a 96-well U bottom plate at a concentration of 100,000
cells per 100 μl per well. To obtain stimulator cells, per-
ipheral blood buffy coat mononuclear cells were
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red blood cell lysis buffer (Sigma-Aldrich) was added for
10 min at 37°C. 100,000 stimulator cells were added to
a tube containing 10,000 MSCs or SB623 cells; and the
mixed cells were then centrifuged and re-suspended at
110,000 mixed cells per 100 μl. 100 μl of stimulator/
MSC cell mix or 100 μl of stimulator/SB623 cell mix
was added to each well of CFSE-responder cells. To
assess the activation state of T cells in the MLR, cells
were harvested on Day 2 and stained with a fluoro-
chrome conjugated antibody against CD69 (BD
Bioscience), an antigen induced on activated T cells. To
monitor cell proliferation kinetics of T cells in the MLR,
cells were harvested on Day 7 and stained with PE-con-
jugated CD4 antibody (BD Bioscience). Flow cytometry
data acquisition was done on BD FACS Calibur, gating
on CD4+ lymphocyte gate, and analysis was done using
CellQuestPro.
Xenogeneic MLRs were established using postnatal
day 9 Sprague-Dawley rat glial mix cells as stimulators
and human peripheral blood T cells as responders.
Briefly, rat brains were harvested and triturated prior to
treatment with 0.25% trypsin (Invitrogen) for 30 min.
Cell suspensions were filtered through a 70 μMc e l l
strainer and overlaid on Ficoll prior to density centrifu-
gation. Glial mix cells were cultured in DMEM/F12
(Mediatech)/10%FBS/pen-strep for 14 days prior to use
in the MLR. Xenogeneic MLRs were performed at a
similar cell ratio as allogeneic MLRs (100,000 glial mix:
100,000 CFSE-labeled human T cells: 10,000 MSCs or
SB623 cells) over a 5-day period. CFSE dilution of
human CD3-gated T cells was assessed by flow
cytometry.
Statistics
Statistical assessments (SigmaStat, Systat Software, Chi-
cago, IL) were made for SB623 or MSC groups to deter-
mine if there were differences either between those two
groups or in some cases compared to the internal assay
controls. To compare co-cultures with SB623 cells to
those with MSCs (n = 3-6 matched lots), Tukey’sp a i r -
wise comparisons were made. To compare co-cultures
with SB623 cells or MSCs to internal experimental con-
trols (when n>1), a general linear model ANOVA, fol-
lowed by Tukey’s pairwise comparisons was used. An
alpha value of 0.05 was used to assess if the means were
significantly different. Data are reported as mean ± stan-
dard deviation.
Results
Comparison of SB623 cells with the corresponding
parental MSCs
SB623 cells were expanded from human MSCs after
transfection with an NICD1-expressing plasmid - a
process that takes eight to ten weeks in culture (Addi-
tional File 1A). Morphologically, SB623 cells retained
the mesenchymal appearance similar to the parental
MSCs. However, in each tested culture of SB623 cells,
the frequency of beta-galactosidase-positive cells was
higher than the parental MSC cultures, suggesting the
presence of senescent cells in SB623 cell culture (Addi-
tional File 1B). qRT-PCR for the exogenous NICD1 gene
and Hes1, a downstream target of Notch signaling, vali-
dated the high expression of exogenous NICD1 DNA
and the induction of endogenous Hes1 transcript after
transfection (Additional File 1C). Intracellular flow cyto-
metry analysis of NICD1 confirmed its reduction over
increasing passages consistent with transient transfection
(Additional File 1D).
To measure cell proliferation in culture, we plated
one million MSCs or SB623 cells and used trypan blue
exclusion to count the number of viable cells on Day
3 .T h er e s u l t ss h o w e dah i g h e rn u m b e ro fv i a b l ec e l l
counts for MSC culture than for SB623 cell culture,
suggesting a lower proliferative index for SB623 cells.
We next assessed the cell cycle profile by staining the
cells with propidium iodide, a DNA intercalating dye,
after fixation and permeabilization. We observed a sig-
nificantly higher number of cells in G0/G1 resting
phase (p < 0.05) in SB623 cultures, again suggesting
reduced proliferation in SB623 cells (Figure 1A). Lastly,
to monitor cell division kinetics over a 5-day growth
culture, we opted for the use of CFSE, a cell permeable
dye which is diluted with each cell division (Figure 1B).
We noted a persistence of a small number of CFSE-
high cells within each lot of SB623 cells and this was
not observed in parental MSC where the vast majority
of cells proliferated.
P16Ink4A is a negative cell cycle regulator and has
been shown to be upregulated in human senescent MSC
[6,7]. To determine whether the CFSE-high (low/no pro-
liferating) cells express p16Ink4A, intracellular staining
for the p16Ink4 protein was performed in CFSE-labeled
cells after culture. The subpopulation of SB623 cells
expressing p16Ink4A corresponded to the CFSE-high
SB623 cells, consistent with the role of p16ink4A as a
negative regulator of cell cycle entry (Figure 1B). Collec-
tively, the results demonstrate that within each final lot
of SB623 cells, there is a small number of non-prolifer-
ating cells.
Phenotypically, SB623 cells expressed all the standard
mesenchymal surface markers (CD73. CD105, CD29,
CD44, CD106). However, CD44 and CD73 were
expressed at significantly higher density per cell as
shown by mean fluorescent intensity (Figure 2A). CD54,
an inter-cellular adhesion molecule not commonly pre-
sent on MSCs, was detectable on a small number of
cells within each lot of SB623 cells.
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Tate et al. characterized the secretome profile of SB623
cells compared to parental MSCs [2]. Here, using intra-
cellular cytokine detection by flow cytometry, we com-
pared the expression of trophic factors in SB623 cells
and the corresponding parental MSCs by inhibiting pro-
tein secretion with BrefeldinA. The results demonstrate
that although the amount of cytokines (IL-6, GM-CSF,
IL-1a, VEGF-A, and TGFb1) expressed varied between
different lots, there was a general trend towards a small
but detectable increase in IL-6 and GM-CSF intracellu-
lar protein expression in lots of SB623 cells compared
to the corresponding lots of parental MSCs (Figure 2B).
SB623 cells suppress T cell activation and proliferation
comparable to parental MSCs in mixed lymphocyte
reaction (MLR)
Senescent cells have been shown to produce higher
levels of pro-inflammatory factors than their younger
counterparts [9]. Because we observed a small number
of senescent-like cells within each lot of SB623 cells, we
next compared the immunosuppressive activity of SB623
cells and the corresponding parental MSCs in the allo-
geneic mixed lymphocyte reaction. On Day 0, 10,000
SB623 cells or MSCs were added to each well of allo-
geneic mixed lymphocyte reactions (MLR), consisting of
100,000 CFSE-labeled peripheral blood enriched T cells
and 100,000 peripheral blood mononuclear cells from
unrelated donors. On Day 2, we assessed the induction
of CD69, an early T cell activation marker. As shown in
Figure 3A, the T cell activation marker, CD69, was
robustly induced in the allogeneic MLR, validating the
functionality of the assay. In the presence of SB623
cells, the percentage of CD4+ helper T cells expressing
CD69 was reduced and this was comparable to the per-
cent reduction seen with the parental MSCs. On Day 7,
gating on CD4 immunostained T cells, we evaluated
CFSE-dilution as an indicator of CD4+ helper T cell
p r o l i f e r a t i o ni nM L R .A ss h o w ni nF i g u r e3 B ,i nt h e
absence of MSC or SB623 cells, more than 80% of the
Figure 1 SB623 cells proliferate more slowly and express more p16Ink4A than parental MSCs. A) Cell proliferation assessed by cell counts
(with trypan blue exclusion; left plot) and the percentage of G0/G1 cells measured by propidium iodide staining (middle plot) reveal a significant
reduction in proliferation for SB623 cells compared to parental MSCs (*p < 0.05; n = 6); Far right shows representative FACS data for determining
cell cycle profile. B) Cell division kinetics assessed by CFSE dilution and p16Ink4A protein by intracellular flow cytometry show a significant
increase in p16Ink4A in SB623 cells versus parental MSCs (*p < 0.05); Representative FACS data on left and the mean expression for 4 different
matched lots of MSC and SB623 cells on right.
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cells, proliferation was significantly reduced (p < 0.05),
comparable to the parental MSCs.
HLA-DR expression is known to be induced on acti-
vated T cells and on antigen presenting cells [12]. We
assessed the percentage of HLA-DR-expressing cells
within each MLR well as an additional measurement of
cell activation. We demonstrated a significant reduction
in HLA-DR-expressing cells when either SB623 cells or
MSCs were included in the MLR (Figure 3C). These
results from allogeneic MLR suggest that SB623 cells
retain immunosuppressive activity comparable to their
parental MSCs.
Transplantation of SB623 cells into rodents following
experimental stroke has been performed via direct injec-
tion into recipient brain along with immunosuppressive
drug administration [3-5]. To determine if SB623 cells
and the parental MSCs can suppress T cell proliferation
in a xenogeneic MLR, we isolated glial mix cells (astro-
cytes+microglia) to be used as stimulators for human
CFSE-labeled T cells. By flow cytometry analysis gating
on CD3, a marker present on all T cell subsets, we
demonstrate that the addition of the parental MSCs as
well as SB623 cells reduced the proliferation of human
T cells in the xenogeneic MLR (Figure 4).
SB623 cells support the generation of peripheral blood
Treg-like cells comparable to parental MSCs
One of the mechanisms by which MSCs suppress
immune activity is through the support for regulatory
T (Treg) cell development [13-15]. IL-2, TGFb1a n d
Notch ligands have all been shown to enhance regula-
tory T cell (Treg) differentiation [16-21]. To assess
the potential of SB623 cells in supporting regulatory
T cells in culture, we performed a 1:10 peripheral
b l o o de n r i c h e dTc e l l s - t o - M S C so rS B 6 2 3c e l lc o - c u l -
ture in the presence and absence of IL-2 over a 7 day
period. CD25 expression on non-activated CD4+ T
cells is commonly used as one of the identity markers
for Tregs [22,23]. We therefore assessed the percen-
tage of CD4+CD25+ cells within each culture and
found significantly more CD4+CD25+ cells in co-cul-
tures with SB623 cells than with MSCs for one of
two blood donors tested (p < 0.05, Figure 5A).
Another marker commonly used to identify Tregs is
the transcription factor, FoxP3. By intracellular
Figure 2 Surface marker and cytokine expression profile of SB623 cells compared to parental MSCs. A)P l o t ss h o w i n gs u r f a c em a r k e r
expression on SB623 cells and MSCs. Both SB623 cells and MSCs have >95% expression of CD44, CD73, and CD105, however, there is an
increase in fluorescence intensity (measured by FACS) of these markers in SB623 cells compared to parental MSCs (*p < 0.05, n = 3, left plot);
there is consistently higher expression of CD54 in SB623 cells versus matched lots of parental MSCs (right plot); B) Plots showing mean
fluorescence intensity of IL-6, GM-CSF, IL-1A, TGFb1, and VEGF-A (measured by intracellular antibody staining and flow cytometry) for 3 different
matched lots of MSC and SB623 cells.
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against FoxP3 (clone PCH101) and analysis by flow
cytometry, we demonstrate that the presence of
MSCs and SB623 cells increased the detection of
FoxP3-expressing T cells in the presence (>8% FoxP3
+) of IL-2 (Figure 5B). And lastly, Tregs have been
reported to constitutively produce IL-10. Therefore,
by intracellular staining with fluorochrome conjugated
antibody against IL-10, we assessed the percentage of
T cells producing IL-10 in IL-2 treated T cell co-cul-
t u r e dw i t he i t h e rM S C so rS B 6 2 3c e l l s .T h er e s u l t s
demonstrate that MSCs and SB623 cells both
enhanced the detection of IL-10 expressing T cells
cultured in the presence of IL-2, compared to culture
with only IL-2 (Figure 5C).
SB623 cells alter the activated immune secretome profile
similar to MSCs
Independent studies suggest that MSCs skew the acti-
vated cytokine profile of immune cells, from a pro- to
anti-inflammatory state [24,25]. Receptor ligands such as
Notch ligand and TGFb1 have immunomodulatory
activity and can be presented by various environmental
cells, including MSCs. As SB623 cells express the Notch
ligand Jagged-1 (Figure 6A) and TGFb1( F i g u r e2 ) ,w e
performed additional cellular immune assays of human
T cells co-cultured with either SB623 cells or MSCs fol-
lowed by sub-optimal doses of PMA/Ionomycin in the
presence of BrefeldinA on Day 7 to monitor the acti-
vated immune secretome profile by intracellular anti-
body staining for specific cytokines.
Figure 3 MSC and SB623 attenuate T cell activation and proliferation in human allogeneic mixed lymphocyte reaction. CFSE-labeled
human enriched T cells plus allogeneic PBMCs were cultured with or without MSCs or SB623 cells. A) CD69 on day 2, B) non-dividing T cells
(M1 gating on CFSE-high cells), and C) The percentage of cells expressing HLA-DR were assessed on day 5 by flow cytometry. Representative
FACS data and the mean expression for 3 different matched lots of MSC and SB623 cells are shown. *p < 0.05 versus T cells alone; #p < 0.05
versus MLR.
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either SB623 cells or MSCs in the presence or absence
of exogenous IL-23 for 7 days. Intracellular detection of
IL-17A expression by flow cytometry demonstrated a
small percentage of IL-17A expressing T cells, averaging
to less than 1.5% (Figure 6C). For Th1 cells, enriched T
cells were co-cultured with either SB623 cells or MSCs
in the absence of exogenous cytokines. As Th1 can
secrete both IFN-g and IL-10, we performed dual stain-
ing for these two cytokines to determine if the inclusion
of SB623 cells skewed the activated immune secretome.
We demonstrate that the inclusion of either MSCs or
SB623 cells resulted in robust skewing of the activated
immune secretome profile with more than 20% of the
cells expressing IL-10 with less than 0.5% of the cells
expressing IFN-g in cultures that included either MSCs
or SB623 cells.
SB623 cells impede monocyte-to-dendritic cell
differentiation in a manner comparable to parental MSCs
Another immunomodulatory property of MSCs lies in
their ability to block monocyte differentiaton along the
d e n d r i t i cl i n e a g e[ 2 6 - 3 0 ] .B yc y t o k i n ea r r a y ,w ep r e -
viously identified IL-6 and VEGF as being secreted by
SB623 cells [2]. Both of these cytokines have been
shown to regulate dendritic cell differentiation and
maturation [31-34]. To determine if SB623 cells can
prevent monocytic differentiation to the dendritic line-
age, we performed a 1:10 co-culture of SB623 cells with
peripheral blood monocytes in the presence of IL-4 and
GM-CSF. In parallel, we established co-cultures with the
parental MSCs. After 7 days, phase contrast microscopy
pictures were taken and each culture was stained with
fluorochrome conjugated antibodies against CD14, a
surface marker of monocytes, and CD1a, a surface mar-
ker of dendritic cells. As shown in Figure 7A, in the
absence of SB623 cells or MSCs, dendritic cell clusters
were readily visible. In contrast, such clusters were
rarely seen in co-cultures with SB623 cells or MSCs. By
flow cytometry, we noted that in the presence of IL-4
and GM-CSF, there was a conversion of CD14+CD1a+
dendritic cell precursors to predominantly CD14-CD1a+
dendritic cells. In contrast, when SB623 cells or parental
MSCs were included in the monocyte-dendritic cell dif-
ferentiation cultures, the transition was significantly
reduced (Figure 7B). These results demonstrate that
SB623 cells retain the ability to suppress monocytic-den-
dritic cell differentiation.
SB623 cells impede dendritic cell maturation better than
parental MSCs
Studies show that IL-6 can block dendritic cell matura-
tion in vivo [33] while VEGF inhibits maturation in
response to lypopolysaccharides (LPS) in vitro [34]. As
shown in Figure 2, SB623 cells secrete both IL-6 and
VEGF. To assess the ability of SB623 cells to dampen
dendritic cell maturation, peripheral blood monocytes
cultured for 7 days with GM-CSF and IL-4 were stimu-
lated with TNF-a for an additional 48 hrs to promote
maturation. SB623 cells or MSCs were added during
this 48 hr stimulation. Two additional conditions -
TNF-a alone or TNF-a + Cyclosporine A - were used
as internal controls. At each endpoint, the expression
levels of the T cell co-stimulatory molecule CD86 were
assessed by flow cytometry (Figure 7C). Consistent with
a previously published report [11], Cyclosporine A
inhibited the induction of co-stimulatory molecule
CD86, compared to conditions with TNF-a alone. Both
Figure 4 MSCs and SB623 cells attenuate human T cell proliferation in xenogeneic mixed lymphocyte reaction. PKH26 -labeled human
CD3+ T cells plus rat mixed glial cells were co-cultured with or without MSCs or SB623 cells. PKH26 flow cytometry analysis gating on human
CD3+ T cells was performed after 5 day co-culture with M1 gating on non-dividing T cells. Representative FACS data shown on top and the
mean expression for 3 different matched lots of MSC and SB623 cells on bottom.
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levels. Notably, SB623 cells were significantly more
effective than MSCs (p < 0.05).
Discussion
Ex vivo manipulation of MSCs has been shown to
induce their cellular senescence [6,7] and senescent cells
have been described to have a pro-inflammatory secre-
tome [8-10]. Because SB623 cells are derived from ex
vivo manipulated MSCs, we investigated the possible
senescent onset in multiple lots of SB623 cells and
compared the immunomodulatory activity of SB623
cells to that of the parental MSCs.
Morphologically, SB623 cells resemble their parental
MSCs. Phenotypically, SB623 cells expressed all the
standard MSC surface markers (CD90, CD105, CD29,
CD44, CD73), although there was an increased density
of CD44 and CD73. A small number of SB623 cells
expressed surface CD54, an inter-cellular adhesion
molecule serving as the ligand for LFA-1, the lympho-
cyte function-associated antigen. SB623 cells displayed a
similar cytokine expression profile as parental MSCs.
The effect of Notch in MSCs has been under much
Figure 5 Detection of CD25, FoxP3, and constitutive IL-10 in T cells co-cultured with MSCs or SB623 cells in the presence of
exogenous IL-2. Human T cells were co-cultured with MSCs or SB623 cells plus hIL-2 for 7 days. A) CD4 and CD25 surface expression with
representative FACS data (left) and the mean expression for 5 different matched lots of MSC and SB623 cells (right); For “Donor 1 PBL”, there is a
significant increase in CD4+CD25+ cells when T cells were co-cultured with SB623 cells versus parental MSCs (*p < 0.05). B) The percentage of
FoxP3-positive T cells as measured by intracellular staining with PE-conjugated antibody against FoxP3 followed by flow cytometry acquisition
and analysis. The bar graphs represent the mean percentage of FoxP3-expressing T cells after co-culture without or with 3 different matched lots
of MSC and SB623 cells. C) To assess the basal constitutive expression of IL-10, BrefeldinA (1:1000) was added during the last 6 hours of culture
to inhibit the secretory pathway. By intracellular staining with a fluorochrome conjugated antibody against IL-10 and analyzed by flow
cytometry. Shown here is a representative flow cytometry data data (left) and the mean expression for 3 different matched lots of MSC and
SB623 cells (right) looking at the percentage of cells staining positive for intracellular IL-10 protein.
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Page 9 of 14investigation. One study has implicated a function of
Notch in promoting cellular senescence of rodent cells
[35]. In our system, we transiently expressed NICD in
human MSCs by DNA plasmid transfection. Analyzing
for two senescent markers - beta-galactosidase positivity
and p16Ink4A expression, we noted a small number of
senescent-like cells within each lot of SB623 cells. From
cell cycle profile and kinetics, we observed reduced pro-
liferation in SB623 cultures compared to the parental
MSCs. This reduced proliferation is most likely not
mediated by exogenous NICD transient expression as
we observed similar reduction in growth for MSCs
transfected with an empty expression vector (data not
shown). Therefore, we suspect that the small number of
senescent-like cells within each lot of SB623 cells is a
reflection of the extended time in culture (~2 months).
As noted above, some studies have highlighted the
pro-inflammatory secretome of senescent cells [8-10].
To date, we did not observe immunological side effects
from SB623 cell implantation in rats. Nevertheless, as
we noted a small population of senescent-like cells
within each lot of SB623 cells, we initiated various cellu-
lar immune assays to compare their immunomodulatory
activity to parental MSCs in more detail. In an allo-
geneic mixed lymphocyte reaction (MLR), we demon-
strated that similar to MSCs, SB623 cells attenuated the
activation of CD4+ T cells as evident by reduction in
CD69 (an early T cell activation marker) and HLA-DR
(an activation marker on both T cells and monocytes).
In experimental rodent stroke, intracerebral implanta-
tion of SB623 cells elicits functional recovery [5]. As the
glial cells are among the common antigen presenting
Figure 6 MSCs and SB623 cells skew the “activated” T cell secretome profile. Human T cells were co-cultured with MSCs or SB623 cells for
7 days in the absence of exogenous cytokines. To measure the activated T cell secretome profile, the cultures were stimulated with suboptimal
doses of PMA/Ionomycin and Brefeldin A for an additional 6 hr prior to intracellular flow cytometry analysis of cytokines. A) Representative FACS
analysis of Jagged-1 surface expression on MSC and SB623 cells prior to co-culture. B) Intracellular detection of IFN-g and IL-10 of T cells after co-
culture with or without MSCs or SB623 cells; Representative FACS data (left) and mean expression for 3 different matched lots of MSC and SB623
cells (right). C) Intracellular detection of IL-7A of T cells after co-culture with MSCs or SB623 cells in the presence or absence of IL-23. Negative
controls include T cells cultured in RPMI/10%FCS alone and T cells cultured in the presence of IL-23 alone.
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SB623 cells in suppressing the proliferation of human T
cells stimulated by rat glial mix cells. We demonstrate
that SB623 cells elicited immunosuppressive activity in
this xenogeneic MLR assay, comparable to parental
MSCs.
In the context of immune modulation, MSCs have
been reported to impact both the innate and acquired
immune cells [25]. In a standard mono-dendritic cell
differentiation assay with GM-CSF and IL-4, we demon-
strate that the inclusion of SB623 cells in the mono-
dendritic cell differentiation culture reduced the produc-
tion of dendritic cells (CD1a+CD14-) to similar extent
as the parental MSCs. In a 2-day TNF- a mediated den-
dritic cell maturation assay, the inclusion of SB623 cells
reduced the density of CD86 co-stimulatory molecules,
as measured by mean fluorescent intensity. Interestingly,
the reduction in CD86 surface expression was signifi-
cantly higher in the presence of SB623 cells than the
parental MSCs. A recent study reported that activated
MSCs secrete soluble TNF-a receptors which, in turn,
attenuate systemic inflammation [36]. As TNF- a is
commonly used to induce dendritic cell maturation, we
hypothesize that a differential expression and/or secre-
tion of TNF- a receptors between SB623 cells and
MSCs could explain our current observations.
Additional studies are warranted to address this possible
underlying mechanism of action.
To assess the impact of SB623 cells on the acquired
immune cells, we performed co-cultures of human
enriched T cells with SB623 cells or MSCs and assessed
the activated T cell secretome profile following stimula-
tion with sub-optimal dosage of PMA/Ionomycin. By
intracellular staining with antibodies against IL-10 and
IFN-g, we observed a robust skewing in the activated
immune secretome profile with more than 95% of cells
expressing IL-10 and less than 5% expressing IFN-g.
The detection of predominantly IL-10 expressing cells is
in line with previous reports that MSCs promote the
anti-inflammatory secretome of T cells. The lack of
IFN-g production was unexpected since Th1 cells are
known to produce both IFN-g and IL-10, not just IL-10
alone. However, IL-10 has been shown to downregulate
IFN-g production [37-39]. It is therefore possible that in
t h ep r e s e n c eo fS B 6 2 3c e l l so rM S C s ,t h el e v e lo fI L - 1 0
produced was high enough to form a negative feedback
loop on the production of IFN-g.Af e ws t u d i e sh a v e
highlighted the production of IL-10 from Th1 T cells as
a “self-control” mechanism [40,41] and Notch activation
has been associated with this process [42]. TGFb1a n d
IL-6, both of which are known to be produced by
MSCs, have a role in Th17- and Th1- T cell
Figure 7 MSCs and SB623 cells interfere with monocyte-DC differentiation and maturation. Human monocytes were differentiated along
the dendritic lineage with GM-CSF+IL-4, with or without MSCs or SB623 cells. A) Phase contrast images illustrating monocytic cell clustering; B)
CD1A and CD14 staining on day 7. Representative FACS data (above) and mean expression for 3 different matched lots of MSC and SB623 cells
(below); the percentage of cells co-expressing CD14 and CD1A after GM-CSF+IL-4 culture is significantly higher when monocytes were cultured
with either MSCs or SB623 cells versus alone (#p < 0.05); the percentage of CD14-CD1A+ cells is significantly lower when differentiation culture
included either MSCs or SB623 cells versus alone (*p < 0.05); C) CD86 surface expression after 2-day TNF-a treatment; Representative FACS data
(left) and mean fluorescence intensity for 3 different matched lots of MSC and SB623 cells (right); there is a significant decrease in the mean
fluorescent intensity of CD86 co-stimulatory molecule when monocytes were co-cultured with SB623 cells versus parental MSCs (*p < 0.05).
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number of Th17-T cells, we performed co-cultures of T
cells with SB623 cells or MSCs in the presence or
absence of IL-23, a cytokine supportive of human Th17-
T cell development. By intracellular staining with an
antibody against IL-17A, we detected an average of less
than 1.5% Th17-T cells, with no significant differences
between co-cultures with SB623 cells or the parental
MSCs. While it is surprising to see a positive impact of
marrow stromal cells on Th17 cell number in culture,
one study to date has highlighted this property of fetal
marrow stromal cells [43]. It is also important to note
that the percentage of IL-17-producing T cells is rela-
tively low compared to the percentage of IL-10 produ-
cing T cells and thus, may explain why transplantation
of MSC elicits an overall immunosuppressive outcome
[24,25].
Another immunomdulatory property of TGFb1a n d
Notch ligands is in the regulation of regulatory T cells
(Tregs) [13,16,21]. As both TGFb and Notch ligand are
expressed by SB623 cells and the parental MSCs, we
next investigated the impact of SB623 cells on T cells
cultured in the presence of IL-2, a cytokine important in
Treg cell development. In the presence of SB623 cells,
we observed a higher percentage of cells expressing sur-
face CD25, the IL-2 receptor alpha chain. Although
CD25 is commonly used to identify Tregs [22,23], this
surface marker is also present on activated T cells [44].
An alternate common marker for Tregs is the forkhead
family transcription factor FoxP3[45]. By intracellular
staining with an antibody against FoxP3, we demon-
strated a higher percentage of FoxP3+ cells when SB623
cells or MSCs were included. As FoxP3 is not exclu-
sively expressed in Tregs [46], we measured the intracel-
lular expression of IL-10, a cytokine constitutively
produced at low levels by Tregs [47,48]. We consistently
detected a small but higher percentage of CD4+ T cells
expressing IL-10 in cultures with SB623 cells or MSCs
compared to the controls. These results suggest that
SB623 cells, like the parental MSCs, may have a role in
supporting T cells having various features of regulatory
T cells.
SB623 cells are derived from NICD-transfected MSCs
and expanded in the absence of exogenous cytokines. As
such, SB623 cells retained the standard phenotypes and
morphology of conventional MSCs. Compared to the
early passage MSCs, SB623 cells contained a small num-
ber of senescent-like cells as a result of cell expansion
in vitro. Nevertheless, we show here that SB623 cells
effectively suppressed T cell proliferation in MLR and
modulated the T cell secretome profile as efficiently as
the parental MSCs. The current study demonstrate that
the transient overexpression of exogenous NICD with
subsequent expansion of human MSCs preserved, and
in some cases increased, their immunosuppressive
activity.
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